Collagen: A possible prediction mark for gastric cancer

Medical Hypotheses

Volumn 72, Issue 2, 2009, Pages 163-165

  Yin, Ying ^a   Zhao, Yuan ^a   Li, Ai Qing ^a   Si, Jian Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN;

ARTICLE; BASEMENT MEMBRANE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; GENE EXPRESSION; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; STOMACH CANCER;

COLLAGEN; HUMANS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 57749180877     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.09.010     Document Type: Article

References (42)

1. Souza R.F., and Spechler S.J. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 55 6 (2005) 334-351
2. Xue L.J., Su Q.S., Yang J.H., and Lin Y. Autoimmune responses induced by Helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses 70 2 (2008) 273-276
3. Macdonald J.S. Gastric cancer-new therapeutic options. N Engl J Med 355 1 (2006) 76-77
4. Cunningham D., and Chua Y.J. East meets west in the treatment of gastric cancer. N Engl J Med 357 18 (2007) 1863-1865
5. Yasui W., Oue N., Aung P.P., Matsumura S., Shutoh M., and Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric cancer 8 2 (2005) 86-94
6. Matsui H., Kubochi K., Okazaki I., Yoshino K., Ishibiki K., and Kitajima M. Collagen biosynthesis in gastric cancer: immunohistochemical analysis of prolyl 4-hydroxylase. J Surg Oncol 70 4 (1999) 239-246
7. Ohno S., Tachibana M., Fujii T., Ueda S., Kubota H., and Nagasue N. Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int J Cancer 97 6 (2002) 770-774
8. Mazouni C., Arun B., André F., et al. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99 1 (2008) 68-71
9. Fukushige T., Kanekura T., Ohuchi E., Shinya T., and Kanzaki T. Immunohistochemical studies comparing the localization of type XV collagen in normal human skin and skin tumors with that of type IV collagen. J Dermatol 32 2 (2005) 74-83
10. Nakano K.Y., Iyama K.I., Mori T., et al. Loss of alveolar basement membrane type IV collagen alpha3, alpha4, and alpha5 chains in bronchioloalveolar carcinoma of the lung. J Pathol 194 4 (2001) 420-427
11. Misumi S., Iyama K., Honda Y., et al. Differential expression of basement membrane type-IV collagen alpha1, alpha2, alpha5 and alpha6 chains among the histological subtypes of adenoid cystic carcinoma. Virchows Arch 445 1 (2004) 54-62
12. Ikeda K., Iyama K., Ishikawa N., et al. Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region. Am J Pathol 168 3 (2006) 856-865
13. Baba Y., Iyama K., Ikeda K., et al. Differential expression of basement membrane type IV collagen alpha chains in gastric intramucosal neoplastic lesions. J Gastroenterol 42 11 (2007) 874-880
14. Quélard D., Lavergne E., Hendaoui I., et al. A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/beta-catenin signaling. PLoS ONE 3 4 (2008) 1878
15. Cortes-Reynosa P., Robledo T., Macias-Silva M., Wu S.V., and Salazar E.P. Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. Matrix Biol 27 3 (2008) 220-231
16. Clamp A.R., and Jayson G.C. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 93 9 (2005) 967-972
17. Sun J., Ding I., Fenton B., Yi W.S., and Okunieff P. Immunohistochemical identification and localization of endogenous endostatin and its related peptides in murine tumors. Adv Exp Med Biol 599 (2007) 147-153
18. Marneros A.G., and Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol 20 5-6 (2001) 337-345
19. Boosani C.S., and Sudhakar A. Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. Protein Expr Purif 49 2 (2006) 211-218
20. Floquet N., Pasco S., Ramont L., et al. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J Biol Chem 279 3 (2004) 2091-2100
21. Shahan T., Grant D., Tootell M., et al. Oncothanin, a peptide from the alpha3 chain of type IV collagen, modifies endothelial cell function and inhibits angiogenesis. Connect Tissue Res 45 3 (2004) 151-163
22. Hamano Y., and Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 333 2 (2005) 292-298
23. Colorado P.C., Torre A., Kamphaus G., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60 9 (2000) 2520-2526
24. Sudhakar A., Nyberg P., Keshamouni V.G., et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115 10 (2005) 2801-2810
25. Magnon C., Galaup A., Mullan B., et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 65 10 (2005) 4353-4361
26. He G.A., Luo J.X., Zhang T.Y., Hu Z.S., and Wang F.Y. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem Biophys Res Commun 318 2 (2004) 354-360
27. Chung IS, Son YI, Ko YJ, Baek CH, Cho JK, Jeong HS. Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol 2008, doi:10.1016/j.oraloncology.2008.01.017.
28. Mimori K, Fukagawa T, Kosaka Y, et al. A Large-Scale Study of MT1-MMP as a Marker for Isolated Tumor Cells in Peripheral Blood and Bone Marrow in Gastric Cancer Cases.Ann Surg Oncol 2008, doi:10.1245/s10434-008-9916-z.
29. Fujimoto D., Hirono Y., Goi T., Katayama K., and Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res 28 2 (2008) 847-854
30. Su C.Q., Qiu H., and Zhang Y. Localization of keratin mRNA and collagen I mRNA in gastric cancer by in situ hybridization and hybridization electron microscopy. World J Gastroenterol 5 6 (1999) 527-530
31. Watanabe M., Hirano T., and Asano G. Roles of myofibroblasts in the stroma of human gastric carcinoma. Nippon Geka Gakkai Zasshi 96 1 (1995) 10-18
32. Hippo Y., Taniguchi H., Tsutsumi S., et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62 1 (2002) 233-240
33. Oue N., Hamai Y., Mitani Y., et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64 7 (2004) 2397-2405
34. Jinawath N., Furukawa Y., Hasegawa S., et al. Comparison of gene-expression profiles between diffuse and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 23 40 (2004) 6830-6844
35. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet 33 1 (2003) 49-54
36. Ossandon F.J., Villarroel C., Aguayo F., et al. In silico analysis of gastric carcinoma Serial Analysis of Gene Expression libraries reveals different profiles associated with ethnicity. Mol Cancer 7 (2008) 22
37. Yasui W., Oue N., Ito R., Kuraoka K., and Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 95 5 (2004) 385-392
38. Woo I.S., Kim K.A., Jeon H.M., et al. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma. Int J Cancer 119 12 (2006) 2901-2906
39. Koç M., Göçmen E., Kiliç M., Ozbay M., Oktem M., and Tez M. Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology 53 70 (2006) 616-618
40. Korenaga D., Funahashi S., Yano K., Maekawa S., Ikeda T., and Sugimachi K. Relationship between peritoneal collagen type IV concentrations and the presence of disseminated metastases in gastric cancer. Arch Surg 130 7 (1995) 769-773
41. Gao Z.L., Zhang C., Du G.Y., and Lu Z.J. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology 54 77 (2007) 1591-1595
42. Ogawa K., Naritaka Y., Katsube T., Ohtani Y., Yagawa H., and Kajiwara T. Clinical studies of type-I procollagen carboxyterminal peptide in serum of patients with gastric cancer: comparison with CEA and CA19-9. J Gastroenterol 29 3 (1994) 250-256